FDA rule would allow generic drugmakers to update labels
The Food and Drug Administration (FDA) plans to issue a new rule that will allow generic drugmakers to make changes to their drugs labeling.
July 05, 2013 at 05:00 AM
4 minute read
The original version of this story was published on Law.com
The Food and Drug Administration (FDA) plans to issue a new rule that will allow generic drugmakers to make changes to their drugs' labeling.
Federal law dictates that generic drug labels must be identical to their brand-name counterparts' labels. Currently, generic manufacturers aren't allowed to update their drug labels even if they learn of a potential safety issue that isn't included on the existing label.
The FDA's new rule, which the agency plans to issue by September, would make generic and brand-name drug companies equally responsible for drug safety. An FDA spokeswoman told the Wall Street Journal that it was too early to know precisely how the agency would word the new rule.
The rule could vastly alter the drug litigation landscape. Generic manufacturers are currently shielded from liability when their drugs cause harm to patients. In the 2011 case Pliva v. Mensing, the Supreme Court ruled that federal labeling laws preempted plaintiffs' liability suits against generic drugmakers.
Sen. Patrick Leahy, D-Vt., praised the proposed rule. “A consumer should not have her rights foreclosed simply because she takes the generic version of a prescription drug,” he told the Journal. “I welcome this first step by the Food and Drug Administration to address this troubling inconsistency in the law.”
For more information, read the New York Times and Reuters.
For more InsideCounsel stories about pharmaceuticals, read:
The Food and Drug Administration (FDA) plans to issue a new rule that will allow generic drugmakers to make changes to their drugs' labeling.
Federal law dictates that generic drug labels must be identical to their brand-name counterparts' labels. Currently, generic manufacturers aren't allowed to update their drug labels even if they learn of a potential safety issue that isn't included on the existing label.
The FDA's new rule, which the agency plans to issue by September, would make generic and brand-name drug companies equally responsible for drug safety. An FDA spokeswoman told the Wall Street Journal that it was too early to know precisely how the agency would word the new rule.
The rule could vastly alter the drug litigation landscape. Generic manufacturers are currently shielded from liability when their drugs cause harm to patients. In the 2011 case Pliva v. Mensing, the Supreme Court ruled that federal labeling laws preempted plaintiffs' liability suits against generic drugmakers.
Sen. Patrick Leahy, D-Vt., praised the proposed rule. “A consumer should not have her rights foreclosed simply because she takes the generic version of a prescription drug,” he told the Journal. “I welcome this first step by the Food and Drug Administration to address this troubling inconsistency in the law.”
For more information, read the
For more InsideCounsel stories about pharmaceuticals, read:
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllWhy Seemingly Simple Off-Channel Communication Rules Still Vex Finance Industry
5 minute readTrending Stories
- 1The Law Firm Disrupted: Playing the Talent Game to Win
- 2Preparing Your Law Firm for 2025: Smart Ways to Embrace AI & Other Technologies
- 3BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 4GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
- 5A&O Shearman Adopts 3-Level Lockstep Pay Model Amid Shift to All-Equity Partnership
Who Got The Work
Blank Rome partner Andrew T. Hambelton has stepped in to defend Fragrancenet.com in a pending trademark infringement lawsuit. The case, filed Aug. 29 in New York Southern District Court by the Blakely Law Group, targets the defendants for allegedly selling counterfeit fragrance products. The case, assigned to U.S. District Judge Lorna G. Schofield, is 1:24-cv-06521, Abercrombie & Fitch Trading Co. v. Quester (US) Enterprises, Inc. et al.
Who Got The Work
Davis Polk & Wardwell partners Mari Grace and Edmund Polubinski III have entered appearances for Australia-based Bitcoin-mining company Iris Energy and other defendants in a pending securities class action. The action, filed Oct. 7 in New York Eastern District Court by the Rosen Law Firm, contends that the defendants concealed the inadequacy of the company's site in Childress County, Texas, including it being 'ill-equipped' and unable to operate the company's proprietary design. The case, assigned to U.S. District Judge Peggy Kuo, is 1:24-cv-07046, Williams-Israel v. Iris Energy Limited et al.
Who Got The Work
Ryan S. Stippich of Reinhart Boerner Van Deuren has entered an appearance for biopharmaceutical company Veru Inc. and other defendants in a pending shareholder derivative lawsuit. The action, filed Sept. 30 in Wisconsin Western District Court by the Brown Law Firm on behalf of June Ovadias, accuses the defendant of failing to disclose that small sample sizes and other issues rendered it unlikely that the FDA would grant Emergency Use Authorization for the cancer drug candidate sabizabulin as a potential treatment for COVID-19. The case, assigned to U.S. District Judge William M. Conley, is 3:24-cv-00676, Ovadias, June v. Steiner, Mitchell et al.
Who Got The Work
Holland & Knight partners Cynthia A. Gierhart and Thomas Willcox Brooke have entered appearances for Pakistani American Political Action Committee and Rao Kamran Ali in a pending trademark infringement lawsuit. The action, filed Sept. 24 in District of Columbia District Court by Jackson Walker on behalf of Pakistani American Public Affairs Committee, accuses the defendants of using a mark that's confusingly similar to the plaintiff's 'Pak-Pac' marks without authorization. The case, assigned to U.S. District Judge Randolph D. Moss, is 1:24-cv-02727, Pakistani American Public Affairs Committee v. Pakistani American Political Action Committee et al.
Who Got The Work
Lauren M. Rosenberg and Yonatan Even of Cravath, Swaine & Moore have stepped in to represent Israel-based Oddity Tech Ltd. in a pending securities class action. The case, filed Aug. 30 in New York Southern District Court by Pomerantz LLP and Holzer & Holzer, contends that the defendant made materially misleading statements regarding the capability of Oddity's AI technology and ongoing civil litigation, resulting in the artifical inflation of the market price of Oddity's securities. The case, assigned to U.S. District Judge Margaret M. Garnett, is 1:24-cv-06571, Hoare v. Oddity Tech Ltd. et al.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250